DK3250575T3 - Tosylatsalt af n-[3-[(4ar,7as)-2-amino-6-(5-fluorpyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluor-phenyl]-5-methoxy-pyrazin-2-carboxamid - Google Patents

Tosylatsalt af n-[3-[(4ar,7as)-2-amino-6-(5-fluorpyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluor-phenyl]-5-methoxy-pyrazin-2-carboxamid Download PDF

Info

Publication number
DK3250575T3
DK3250575T3 DK16702654.1T DK16702654T DK3250575T3 DK 3250575 T3 DK3250575 T3 DK 3250575T3 DK 16702654 T DK16702654 T DK 16702654T DK 3250575 T3 DK3250575 T3 DK 3250575T3
Authority
DK
Denmark
Prior art keywords
fluorpyrimidin
tetrahydropyrrolo
thiazin
pyrazin
carboxamide
Prior art date
Application number
DK16702654.1T
Other languages
English (en)
Inventor
David Andrew Coates
Craig Daniel Wolfangel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3250575T3 publication Critical patent/DK3250575T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK16702654.1T 2015-01-30 2016-01-22 Tosylatsalt af n-[3-[(4ar,7as)-2-amino-6-(5-fluorpyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluor-phenyl]-5-methoxy-pyrazin-2-carboxamid DK3250575T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562109733P 2015-01-30 2015-01-30
PCT/US2016/014423 WO2016122968A1 (en) 2015-01-30 2016-01-22 Tosylate salt of n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide

Publications (1)

Publication Number Publication Date
DK3250575T3 true DK3250575T3 (da) 2020-01-20

Family

ID=55275232

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16702654.1T DK3250575T3 (da) 2015-01-30 2016-01-22 Tosylatsalt af n-[3-[(4ar,7as)-2-amino-6-(5-fluorpyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluor-phenyl]-5-methoxy-pyrazin-2-carboxamid

Country Status (41)

Country Link
US (1) US10080758B2 (da)
EP (1) EP3250575B1 (da)
JP (2) JP6723250B2 (da)
KR (1) KR101950129B1 (da)
CN (1) CN107108657B (da)
AR (1) AR103406A1 (da)
AU (1) AU2016211827B2 (da)
BR (1) BR112017012149A2 (da)
CA (1) CA2969475C (da)
CL (1) CL2017001899A1 (da)
CO (1) CO2017007810A2 (da)
CR (1) CR20170287A (da)
CY (1) CY1122548T1 (da)
DK (1) DK3250575T3 (da)
DO (1) DOP2017000159A (da)
EA (1) EA031330B1 (da)
EC (1) ECSP17048768A (da)
ES (1) ES2768782T3 (da)
GT (1) GT201700166A (da)
HR (1) HRP20192240T1 (da)
HU (1) HUE048029T2 (da)
IL (1) IL252754A0 (da)
LT (1) LT3250575T (da)
MA (1) MA41420B1 (da)
MD (1) MD3250575T2 (da)
ME (1) ME03581B (da)
MX (1) MX2017009713A (da)
NZ (1) NZ732381A (da)
PE (1) PE20171333A1 (da)
PH (1) PH12017501356A1 (da)
PL (1) PL3250575T3 (da)
PT (1) PT3250575T (da)
RS (1) RS59730B1 (da)
SG (1) SG11201706038PA (da)
SI (1) SI3250575T1 (da)
SV (1) SV2017005478A (da)
TN (1) TN2017000332A1 (da)
TW (1) TWI574969B (da)
UA (1) UA119581C2 (da)
WO (1) WO2016122968A1 (da)
ZA (1) ZA201703937B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI574969B (zh) * 2015-01-30 2017-03-21 美國禮來大藥廠 甲苯磺酸鹽
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT401651B (de) * 1994-06-14 1996-11-25 Biochemie Gmbh 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4-
CA2708043C (en) * 2007-12-07 2012-11-13 Pfizer Inc. Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-fluoro-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide
PE20091438A1 (es) * 2008-01-18 2009-09-26 Eisai Randd Man Co Ltd Derivados fusionados de aminodihidrotiazina
TWI593692B (zh) * 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
TWI570127B (zh) * 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
TWI574969B (zh) * 2015-01-30 2017-03-21 美國禮來大藥廠 甲苯磺酸鹽

Also Published As

Publication number Publication date
CN107108657A (zh) 2017-08-29
PH12017501356A1 (en) 2017-12-11
PL3250575T3 (pl) 2020-06-01
IL252754A0 (en) 2017-08-31
JP2018503666A (ja) 2018-02-08
GT201700166A (es) 2018-11-23
EP3250575B1 (en) 2019-11-20
EA031330B1 (ru) 2018-12-28
CY1122548T1 (el) 2021-01-27
SV2017005478A (es) 2018-02-09
EP3250575A1 (en) 2017-12-06
AU2016211827A1 (en) 2017-06-22
SG11201706038PA (en) 2017-08-30
KR20170097782A (ko) 2017-08-28
ECSP17048768A (es) 2017-11-30
CL2017001899A1 (es) 2018-03-23
TWI574969B (zh) 2017-03-21
MA41420B1 (fr) 2020-02-28
RS59730B1 (sr) 2020-02-28
MX2017009713A (es) 2017-11-17
TN2017000332A1 (en) 2019-01-16
HUE048029T2 (hu) 2020-05-28
CA2969475C (en) 2019-06-18
CN107108657B (zh) 2021-10-08
EA201791229A1 (ru) 2017-11-30
PT3250575T (pt) 2020-01-16
CR20170287A (es) 2017-07-20
JP2019142902A (ja) 2019-08-29
KR101950129B1 (ko) 2019-02-19
JP6723250B2 (ja) 2020-07-15
NZ732381A (en) 2018-05-25
AR103406A1 (es) 2017-05-10
HRP20192240T1 (hr) 2020-03-06
CO2017007810A2 (es) 2017-10-20
MD3250575T2 (ro) 2020-03-31
AU2016211827B2 (en) 2018-04-26
DOP2017000159A (es) 2017-07-31
SI3250575T1 (sl) 2019-12-31
BR112017012149A2 (pt) 2018-01-02
ME03581B (me) 2020-07-20
UA119581C2 (uk) 2019-07-10
LT3250575T (lt) 2020-02-10
US10080758B2 (en) 2018-09-25
ES2768782T3 (es) 2020-06-23
CA2969475A1 (en) 2016-08-04
WO2016122968A1 (en) 2016-08-04
ZA201703937B (en) 2019-01-30
PE20171333A1 (es) 2017-09-13
US20170368071A1 (en) 2017-12-28
TW201636354A (zh) 2016-10-16

Similar Documents

Publication Publication Date Title
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK3798222T3 (da) Krystallinsk form af den frie base af lorlatinib
DK3191406T3 (da) Fremgangsmåde til fremstilling af aluminiumchloridderivater
DK3279202T3 (da) Krystal af 3,5-disubstitueret benzenalkynylforbindelse
MA41542A (fr) Nouveaux dérivés de n-acyl-arylsulfonamide utilisés en tant qu'inhibiteurs d'aminoacyl-arnt synthétase
DK3390412T3 (da) Vandopløselige derivater af 3,5-diphenyl-diazolforbindelser
DK3390407T3 (da) Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
MA41842A (fr) Nouveaux procédés de sélection d'épitope
DK3397621T3 (da) Fremgangsmåde til fremstilling af 1,1,3-trioxo-1,2-benzothiazol-6-carboxamid
DK3166354T3 (da) Ændring af dækningsforøgelsestilstand for brugerudstyr med forøget dækning
DK3274331T3 (da) Fremstilling af 4,5,6,7-tetrahydroisozaxolo[5,4-c]pyridin-3-ol
DK3180314T3 (da) Fremgangsmåde til fremstilling af syntetiske mellemprodukter til fremstilling af tetrahydroquinolin-derivater
DK3418273T3 (da) Derivater af flavagliner
DK3430004T3 (da) Faststofformer af nilotinibsalte
DK3250575T3 (da) Tosylatsalt af n-[3-[(4ar,7as)-2-amino-6-(5-fluorpyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluor-phenyl]-5-methoxy-pyrazin-2-carboxamid
DK3397620T3 (da) Fremgangsmåde til fremstilling af 1,1,3-Trioxo-1,2-benzothiazol-6-carboxamid
DK3380453T3 (da) Syntese af beta-mercaptoethanol
DK3515454T3 (da) Krystallinsk polymorf form af 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5-[1,2]oxaphosphinan
DK3042948T3 (da) Solid dyrkningsanordning af den roterende type
DK3526327T3 (da) Mutagenisering af intracellulære nukleinsyrer
DK3524231T3 (da) Stabiliseret præparat af interferon-beta-variant
DK3325489T3 (da) Asymmetrisk fremgangsmåde til fremstilling af thien-indolderivater
DK3328842T3 (da) Fremgangsmåde til fremstillingen af isocarboxazid
DK3468362T3 (da) Emulgerbart koncentrat af tefluthrin